RCM
NBIX icon

Riverhead Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Riverhead Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$253K Sell
2,812
-2,554
-48% -$239K 0.01% 1035
2019
Q2 		$453K Buy
5,366
+5,188
+2,915% +$426K 0.02% 764
2019
Q1 		$16K Buy
178
+36
+25% +$3.01K ﹤0.01% 1478
2018
Q4 		$10K Buy
+142
New +$13.6K ﹤0.01% 1480

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverhead Capital Management's NBIX Position: Q3 2019 in Review

Riverhead Capital Management reduced its Neurocrine Biosciences (NBIX) stake by 48% in Q3 2019, selling an estimated $239K and leaving 2,812 shares worth $253K. The position accounts for 0.01% of the portfolio, ranked #1035.

Riverhead Capital Management first reported a position in NBIX in Q4 2018 and has held it in 4 quarters since. The position peaked at $453K in Q2 2019. 333 funds tracked by Wall St. Rank hold NBIX as of Q3 2019.

  • Riverhead Capital Management held 2,812 shares of Neurocrine Biosciences worth $253K as of Q3 2019.
  • Riverhead Capital Management sold 2,554 Neurocrine Biosciences shares in Q3 2019, an estimated $239K.
  • Neurocrine Biosciences made up 0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1035 holding.
  • Riverhead Capital Management first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 4 quarters since.
  • Riverhead Capital Management's Neurocrine Biosciences position peaked at $453K in Q2 2019.
  • 333 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.